Drug Platform Helps in Research for New Drug Therapies

As medical developments advance, the importance of clinical research in developing new therapies that can treat new ailments and overcome drug-resistant diseases cannot be overstated. At present, the clinical research end of the drug discovery pipeline is slowed by unnecessary layers of complexity, preventing new therapies from reaching patients, and keeping medical technology from being flexible enough to detect outbreaks before they become epidemics.

A typical e-platform--where all parties involved in clinical research can share information easily--solves this critical problem. Clinical Research Information Exchange (CRIX) International has begun work on an electronic platform that will help clinical researchers collaborate across international boundaries and speed innovative therapies to market. This platform has the potential to revolutionize the clinical research and regulatory environments, and is planned for launch early in 2008.

CRIX International (Reston, VA, USA)is particularly noteworthy in that is was able to bring together major companies and research organizations from all areas of healthcare to ensure a wide range of expertise in its development and application. Industry leaders Pfizer and Amgen have already made substantial investments in the CRIX platform and are advocates for its wide adoption.

The CRIX platform will enable standardization and electronic transfer of data, which will speed the development and approval process of clinical trials. The platform also works to correlate patients to trials in both the public and private arenas. The CRIX initiative allows leaders in the life sciences industry to stay focused on science, medicine, and the patient--as opposed to the information technology infrastructure.

The broad adoption of the CRIX platform should support new drug development and cost-effectiveness by allowing faster, increased access to information, increased opportunities for collaboration, and the efficiencies of scale afforded through centralization. The platform will represent private life-science companies, government regulatory bodies, and non-profit organizations working collaboratively to improve public health.

The CRIX platform should provide a unique collaborative environment that speeds new therapies to market. CRIX International is a privately funded, not-for-profit organization dedicated to leveraging technology to accelerate and streamline the interaction between sponsors of new drug products, their business partners, research institutions, academia, and health authorities involved in bringing new therapies to patients throughout the worldwide.


Related Links:
CRIX International